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Abstract
Sterically stabilized immunoliposomes (IL) with diameters of about 135 nm carrying mouse IgG, either coupled directly to the liposome
surface, or linked to the terminal ends of grafted poly(ethylene glycol) (PEG) chains by a recently described conjugation procedure (Cyanur-
PEG-PE), were intravenously injected into rats and the elimination kinetics and biodistribution were determined and compared with control
liposomes. The amounts of conjugated antibodies were about 30 Ag/Amol total lipid for all IL. In naive rats, plain pegylated liposomes
displayed the longest blood circulation time, whereas the terminal-coupled IL exhibited the fastest elimination. Liposomes containing the
underivatized anchor molecules circulate nearly as long as plain pegylated liposomes, indicating that the fast elimination of the IL can be
attributed to the presence of antibodies.
A second injection of identical liposomes 14 days after the first injection had a considerable influence on the pharmacokinetic parameters of
the liposomes. The circulation time of plain pegylated liposomes drastically dropped by half and their uptake by the liver increased
concomitantly, indicating that the PEG, upon repeated injection, ceases to function as an efficient barrier reducing opsonization and/or immune
reactions. The circulation time of conventional IL was moderately reduced upon a second injection, whereas that of the terminally coupled IL
was nearly unaffected. These differences among the IL demonstrate that the pharmacokinetic behavior of IL is strongly dependent on the
antibody conjugation site on the liposome. The observed effects of repeated injections were similar for liposomes of 90-nm diameter. The
phenomena described may have important implications for the repeated application of IL as drug carriers.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Antibody-targeted liposomes, also referred to as immuno-
liposomes (IL), are regarded as promising targeting vehicles
for systemic drug delivery in the treatment of several di-
seases such as cancer [1–3]. The basis of efficient liposomal
drug targeting is a sufficiently long circulation lifetime to
allow escape from the vascular bed. This can be achieved by
sterically stabilizing unilamellar liposomes with surface-
grafted poly(ethylene glycol) (PEG) chains [4,5]. Pegylated
liposomes exhibit a dose-independent prolonged circulation
in blood due to a reduced uptake by cells of the mononuclear
phagocyte system. Thus, pegylated liposomes are able to
accumulate in tumors or at sites of inflammation as a result of
passive targeting [6,7].
For specific targeting purposes, the steric stabilization of
liposomes by PEG can be combined effectively with anti-
body coupling [8,9]. Basically, two types of pegylated IL can
be distinguished: (i) conventional IL with antibodies directly
coupled onto the surface of PEG-containing liposomes
[10,11] and, (ii) IL with antibodies coupled onto the terminal
ends of surface-grafted PEG chains [12–14]. The latter
formulations expose the antibodies in a better accessible
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and more flexible position, which was demonstrated to be
advantageous for targeting purposes. For the preparation of
PEG-terminally coupled IL, a variety of techniques are
available, which differ in the chemistry of the coupling
[12–16]. We recently introduced a conjugation technique,
by which antibodies can be linked directly to a PEG-terminal
cyanuric chloride (Cyanur-PEG-PE) without the need for
prior antibody activation or derivatization [17].
The PEG-terminal IL have been optimized with respect to
circulation half-life and targetability by varying liposome
size, antibody coupling density as well as coupling technique
[16]. However, even the most powerful liposomal drug
formulation in many cases will require repeated administra-
tion. Consequently, it will not suffice to consider only the
elimination kinetics of IL upon first injection. Pharmacoki-
netics of subsequently administered doses are at least equally
important. For example, the use of species-incompatible
antibodies or immunoconjugates might provoke an immune
response of the organism, which in turn may strongly affect
the pharmacokinetic profiles of subsequent doses.
A recent study demonstrated that after a single dose of
plain pegylated liposomes, the pharmacokinetics of subse-
quent doses is substantially altered. The enhanced blood
clearance of the second dose was attributed to immunogenic
reactions evoked by the first injection, involving an uniden-
tified soluble serum factor functioning as opsonin [18].
Several studies describe the adjuvant activity of liposomes
in the immune response to incorporated or surface-attached
protein antigens [19,20]. Despite this obvious immunogenic
potency of IL, only a few studies recognize its significance.
Phillips et al. [21] investigated the immunogenicity in mice
of conventional pegylated IL with mouse IgG, surface
attached via an avidin bridge. They detected a strong
immunogenic reaction, which was even enhanced by the
presence of PEG. In only one study PEG-terminal coupled IL
were considered: Harding et al. [22] attached chimerized
mouse IgG onto hydrazide-reactive PEG derivatives and
administered these IL repeatedly to rats. The decrease in
circulation half-life they observed correlated well with a
significant increase in anti-IgG titers. Because the strong
immune response toward the coupled IgG could be specified
as Fc directed, the coupling of less immunogenic Fab frag-
ments was suggested for future IL applications.
However, these studies neither allow to determine a
correlation between structural parameters of IL and their im-
munogenicity nor do they provide a comparison between
immunogenic potency of conventional versus terminally
coupled IL.
The present study investigates the pharmacokinetic
behavior of repeatedly injected conventional and terminally
coupled IL in rats as an indicator for liposomal immunoge-
nicity. Furthermore, we paid special attention to the bio-
compatibility of the recently described antibody coupling
anchor Cyanur-PEG-PE.
We found that the presence of IgG is an important factor
in the enhanced elimination of liposomes, even upon the first
administration. However, the extent by which circulation
half-life at the second injection is reduced varies among the
liposome preparations. Because the terminally coupled IL
using Cyanur-PEG-PE retain a circulation time which is
slightly higher than for conventional ones, they appear from
this study as acceptable carriers for a liposomal drug therapy.
Obviously, IL cannot indiscriminately be considered as
highly immunogenic; the liposomal structure and antibody
coupling technology are important factors determining the
extent to which liposomal pharmacokinetics are altered upon
repeated administration.
2. Materials and methods
2.1. Materials
Soy phosphatidylcholine (SPC) was obtained from Lucas
Meyer (Hamburg, Germany). Cholesterol (Chol) and 1-ethyl-
3-(3-dimethylaminopropyl)carbodiimide (EDC) were pur-
chased from Sigma (Deisenhofen, Germany). Poly(ethylene
glycol)-PE (PEG-DSPE 2000) was purchased from Avanti
Polar Lipids (Alabaster, AL, USA). [3H]-cholesteryloleyl
ether (3H-COE) was obtained from Amersham (Bucking-
hamshire, UK). These substances were used without further
purification. The membrane anchors for antibody coupling,
Cyanur-PEG-PE and N-glutaryl-phosphatidylethanolamine
(N-Glut-PE) as well as PEG-PE 3000, were synthesized as
previously described [17]. All salts and buffers were of
analytical grade.
The purified murine IgG (reagent grade) was purchased
from Sigma.
2.2. Animals
About 10 weeks old specified pathogen-free male Wag/
Rij rats (Harlan, Horst, The Netherlands) were kept under
standard laboratory conditions with access to standard labo-
ratory chow and water ad libitum.
2.3. Preparation of IL
Large unilamellar vesicles (LUV) were prepared by
extruding multilamellar vesicles. For this purpose, a lipid
film (10 Amol) was suspended in 1 ml aqueous solution (0.15
M HEPES or NaCl) at 60jC. The resulting multilamellar
vesicles were extruded (Extruder, Lipex Biomembrane,
Vancouver, Canada) six times through a polycarbonate filter
with a pore size of 100 nm, followed by extrusion through a
filter with a pore size of 50 nm (Costar, Bodenheim, Ger-
many). Vesicle size was determined by dynamic light scat-
tering using a Malvern Autosizer II c (Malvern, UK) in mass
distribution mode. The lipid composition of vesicles was
adjusted according to the coupling procedure. The basic lipid
composition was SPC/Chol 2:1 (molar ratio), to which either
5 mol% N-glut-PE or 5 mol% Cyanur-PEG-PE were added
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to prepare IL. The addition of PEG-PE 2000 diminished the
fraction of SPC. When required, liposomes were labeled
with trace amounts of 3H-COE (0.25 Ci/mol).
For all coupling procedures, an initial phospholipid/Ab
molar ratio of 1000:1 was chosen, as previously optimized
by Hansen et al. [13]. The coupling yield of all reactions was
quantified with a protein determination assay according to
Peterson [23] and correlated to the actual liposome concen-
tration determined by phosphate assay [24].
Liposomes containing Cyanur-PEG-PE were prepared in
0.15 M NaCl. The indicated amounts of antibodies, which
were dissolved in borate buffer (pH 8.8), were added to this
preparation and incubated at room temperature for about 16 h.
Unbound antibodies were separated by passing the liposomes
over a Sepharose 4B (Sigma) column and eluting them with
phosphate-buffered saline (PBS) pH 7.4.
To form a protein linkage to liposomal N-Glut-PE, 6 mg
EDC was added to 10 Amol liposomes in HEPES (pH 7.4)
followed by a 6-h incubation period at room temperature and
by gel permeation chromatography (Sephadex G 50, Phar-
macia, Sweden) to remove excess EDC. Antibodies were
added and the mixture was incubated overnight at room
temperature. Unbound antibodies were separated from the IL
by gel permeation chromatography on Sepharose 4B.
2.4. Pharmacokinetics and tissue distribution studies
For determination of tissue distribution, 20 Amol total
lipid (TL)/kg of 3H-COE-labeled liposomes was injected
into male Wag/Rij rats (210–250 g) via the penile vein under
light diethyl ether anesthesia. At the indicated times, blood
samples were taken from the tail vein. Twenty-four hours
after injection of the liposomes, rats were anesthetized by
intraperitoneal injection of 20–25 mg sodium pentobarbital
and a blood sample was taken from the inferior vena cava.
After a 3-min perfusion of the liver with PBS (37jC) via the
portal vein, liver, spleen, heart, lungs and kidneys were
removed. The organs were processed for measurement of
radioactivity as described before [25]. Briefly, the organs
were homogenized using a Potter Elvehjem tube. Radio-
activity of the homogenate (0.1–0.4 ml) was determined
after adding 100 Al 10% sodium dodecyl sulfate and 4 ml
scintillation liquid. Blood samples were allowed to clot for at
least 3 h at 4jC followed by centrifugation. The radioactivity
measurements of the serum samples were used to calculate
the total amount of radioactivity in serum according to the
equation: serum volume (ml)=[0.0219 body weight (g)] +
2.66 [25]. Results of serum clearance and organ uptake of
the liposomes were calculated as percentage of the injected
dose.
The pharmacokinetic parameters were calculated by fit-
ting the percentage of injected dose versus time for each rat
taking a compartment free analysis using Topfit version 2.0
[26]. Because the elimination curves do not follow clear first-
order kinetics, we took the time point at which 50% of the
liposomes were eliminated from the blood from the elimi-
nation graphs to allow comparison between the different
types of liposomes, instead of a calculated half-life.
2.5. Determination of anti-PEG-PE antibody titers in serum
The search for anti-PEG-PE antibodies in the 24-h serum
samples was performed by a sandwich ELISA technique.
The ELISA plates (Microlon, Greiner Labortechnik, Ger-
many) were coated with PEG-PE 2000 as described before
[27]. Coating was established by determining phospholipid
phosphorus [24] after solubilization of the coating using
Triton X-100.
Initial serum dilution was 1:5 in PBS. Coated plates were
incubated with serum samples for 90 min at 37jC. After
washing, peroxidase-labeled rabbit (anti-rat IgG) was used to
assay for bound rat antibodies.
3. Results and discussion
3.1. Preparation and characterization of IL
Conventional IL with antibodies directly coupled onto the
liposomal surface were constructed using N-Glut-PE as an
anchor, to which antibodies can be attached after carbodii-
mide activation via an amide bond, as previously described
[17,28]. Five mole percent of PEG-PE 2000 was included in
the lipid mixture to obtain liposomes with long circulation
characteristics.
Terminally PEG-coupled IL were prepared by using
Cyanur-PEG-PE as a membrane anchor [17,29]. To obtain
comparable steric stabilization of all IL, either 5 mol% of
Cyanur-PEG-PE anchor (‘‘Cyanur 5’’) or 3 mol% Cyanur-
PEG-PE plus 2 mol% PEG-PE 2000 (‘‘Cyanur 3’’) was
incorporated.
To avoid immune-specific biodistribution of the IL, we
used an irrelevant, highly purified mouse IgG for coupling to
the liposomes. The coupling reactions did not lead to a
significant increase in particle size (Table 1).
Table 1














142F 6 24F 2.8 30
Cyanur 5 SPC/Chol/Cyanur-
PEG-PE (6.5:3:0.5)





136F 8 26F 4.0 32
Control SPC/Chol/PEG-
PE 2000 (6.5:3:0.5)
131F 7 – –
Data are means (n>5)F S.D.
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The amounts of coupled antibodies of about 30 Ag/Amol
TL used in this study have been shown to be an optimal
compromise between targetability and long circulation of IL
[30,31].
3.2. Single-dose pharmacokinetics of IL
The blood clearance profiles in naive rats in Fig. 1
demonstrate that all preparations display prolonged blood
retention with some minor differences between the prepara-
tions. Control liposomes, without coupled antibodies, dis-
play the longest circulation time. In contrast to previous
reports, the preparations do not show ideal first-order
elimination kinetics. They tend to show biphasic kinetics
with a fast initial elimination during the first 4 h followed by
slower second phase. We tentatively attribute these differ-
ences to the lipid composition used in this study and to the
size of our liposome preparations. We used unsaturated soy
PC as the main phospholipid, which tends to produce less
stable liposomes upon contact with serum (data not shown)
than more rigid saturated phospholipid used by others
[18,22]. When ignoring the biphasic profile and approximat-
ing it as log-linear, we can calculate a half-life for the control
of about 13 h, which is in agreement with several studies on
elimination kinetics of pegylated liposomes [4,16]. The
slightly shorter circulation time than that reported by Har-
ding et al. [22] or Koning et al. [32] might also be attributed
to the larger particle size in our study. It is evident that the
surface-bound antibodies enhance the blood clearance,
because all these IL types display shorter half-lifes than
the control. The pharmacokinetic parameters obtained from
a log-linear approximation for all preparations are summar-
ized in Table 2.
From Table 2, it is also apparent that there is a difference
between conventional and terminally coupled IL. The ter-
minally coupled IL Cyanur 3 and 5 were cleared faster than
the N-Glut-PE IL, which may be attributed to a better
accessibility of the antibody positioned at the PEG terminus.
Liposomes containing Cyanur-PEG-PE without coupled
antibodies circulate slightly longer than the antibody-
coupled liposomes. The accumulation of Cyanur 3 and 5
IL in the liver is higher than that of the other liposomes
(Table 2). The uptake by spleen does not correlate with the
circulation time. Uptake in lungs, kidney and heart was
always below 1% of injected dose (not listed).
3.3. Pharmacokinetics after repeated administration
Most therapeutic applications of liposomes will require
repeated injections. This may lead to immunological reac-
tions, especially when species-incompatible antibody target-
ing is applied, resulting in altered pharmacokinetics. To
evaluate such complications, we analyzed the pharmacoki-
netic behavior of the liposomes upon repeated injection.
Following a first injection with non-labeled liposomes, rats
were reinjected after 14 days with liposomes of the same
composition, containing a trace amount of 3H-COE as a
marker (Fig. 2 and Table 3). It was expected, based on
previous studies, that any change in pharmacokinetic profile
may require 1–3 weeks to develop [18].
Compared to the elimination kinetics of the first dose, the
circulation time of the second dose of plain control lip-
Fig. 1. Pharmacokinetic profiles of plain and antibody-coupled liposomes containing a 3H-COE label in naive rats. Data represent the mean of three
experimentsF S.D.
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osomes was strongly diminished. This confirms similar
observations by Dams et al. [18], who interpreted this as
the result of a reaction of the immune system toward the
first dose, leading to opsonization of the second dose by a
soluble serum factor. Consequently, despite their prolonged
circulation time in naive organisms, normal pegylated lip-
osomes should not be regarded as non-immunogenic.
In view of the behavior of the plain liposomes, we
expected an even faster clearance of a second dose of IL as
a result of the immunogenic effect of the coupled antibodies.
Surprisingly, however, the second dose of IL was not
eliminated faster than the second dose of plain control
liposomes (Fig. 2). In fact, cyanur IL tend to display even
longer circulation times.
The moderate change in elimination rate of the IL sug-
gests that the coupled antibodies of murine origin are either
not strongly immunogenic or they are not readily processed
by cells of the immune system due to the presence of the
PEG chains. The shorter circulation time of a second dose of
the N-Glut-PE liposomes, as compared to that of both
terminally coupled IL with better antibody exposition, does
not support the latter explanation.
The data for the liver uptake are generally in accordance
with the serum elimination values. Whereas the liver uptake
of the Cyanur 3 or 5 IL only moderately increased by about
10–20% compared to the first dose, the liver uptake of the
N-Glut IL and of the controls was drastically increased
(Table 3).
Because the coupled murine antibodies seem to contribute
little to the altered liposome pharmacokinetics after repeated
injection, we further investigated the role of the PEG. Our
results showed that especially the clearance of the liposomes
Fig. 2. Blood clearance curves obtained following a second injection of plain liposomes or IL 14 days after first injection in rats. Data are means of at least three
experimentsF S.D.
Table 2
Pharmacokinetic parameters and organ distribution of different liposomal









Cyanur 3 2.5 605F 96 49.6F 3.0 3.5F 0.03
Cyanur 5 2.5 658F 84 52.3F 4.1 8.1F1.4
N-Glut 3.7 920F 73 30.8F 1.8 5.9F 0.9
Control 5.9 1364F 163 39.0F 2.8 6.4F 1.8
Cyanur 3
without Ab
5.2 917F 89 33.8F 3.0 6.0F 1.1
Data represent the means of three independent experiments.
a Time at which 50%of the liposomes have been removed from the blood;
data obtained from the elimination curves as described in the Materials and
methods section.
Table 3
Pharmacokinetic parameters and organ distribution of different liposomal
preparations labeled with 3H-COE 24 h after a second administration into









Cyanur 3 3.0 715F 62 53.0F 2.1 6.5F 0.5
Cyanur 5 1.3 378F 112 63.3F 4.2 10.9F 1.6
N-Glut 1.4 455F 63 60.7F 3.8 7.4F 1.2
Control 0.8 242F 39 60.6F 4.4 6.4F 1.7
Cyanur 3
without Ab
3.6 828F 89 35.1F 2.1 5.8F 0.7
Control 3000 2.5 315F 35 62.3F 1.8 6.0F 0.9
Data represent the means of three independent experiments.
a Time at which 50%of the liposomes have been removed from the blood;
data obtained from the elimination curves as described in the Materials and
methods section.
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containing PEG-PE 2000 (control and N-Glut-PE) is
enhanced upon second injection, but not that of the Cya-
nur-PEG-PE IL or the Cyanur liposomes without antibodies.
This might imply an immunogenic role of PEG-PE as
already described by Phillips et al. [21]. Because liposome-
induced anti-phospholipid antibodies are known to have a
significant effect on liposome circulation as an intrinsic
adjuvant factor [33], we searched for anti-PEG-PE anti-
bodies in the 24-h serum samples. However, no evidence
was found for the presence of anti-PEG-PE antibodies in the
different serum samples.
Another difference between the IL is the molecular
weight of the PEG derivatives. In contrast to the commonly
used PEG-PE 2000, Cyanur-PEG-PE contains a PEG chain
of a molecular weight of about 3000. Dams et al. [18]
interpreted the strong increase in elimination of liposomes
containing PEG-PE 2000 as the result of opsonization by a
serum component. It is conceivable that the production of
such a factor is modulated by the PEG chain length. There-
fore, we prepared control liposomes containing 5 mol%
PEG-PE 3000. In addition, the second dose of these PEG
3000 liposomes shows a reduced circulation time (Fig. 3)
similar to the PEG 2000 control liposomes. Therefore, there
is no indication that the higher molecular weight of PEG is
responsible for the pharmacokinetic differences between
Cyanur 3 or 5 and the other preparations. Furthermore,
because the Cyanur liposomes without coupled antibodies
circulate much longer (Fig. 2) than control PEG-3000 lip-
osomes, which differ from the former only in the terminal
cyanuric chloride moiety, this emphasizes a potential role of
the PEG terminus in pharmacokinetic behavior.
These data indicate that, although elimination of pegy-
lated liposomes from the circulation is enhanced upon
repeated injection, possibly as a result of an immunogenic
response, the pharmacokinetic behavior of IL is also strongly
dependent on structural parameters, which cannot be gener-
alized easily. A second dose of our terminally PEG-coupled
IL was eliminated with a calculated half-life of more than 6
h, whereas the hydrazide-PEG-coupled IL used by Harding
et al. [22] displayed a half-life of only 0.5 h after the second
injection. They found a much stronger immunogenicity
against coupled whole antibodies compared to coupled Fab
fragments, leading them to recommend the latter for use as
homing devices to minimize immune reactions. Because we
used whole murine IgGs, versus antibodies of human origin
in the study of Harding et al., and because we did not test for
the presence of antibodies against IL in our study, we cannot
directly compare the two studies.
However, considering the pharmacokinetics of plain and
IL in our study, the antibodies display obviously a much
lower influence on pharmacokinetics. Consequently, the
strong immunogenic activity of the IL in the study of Harding
et al. may be related to liposomal characteristics, such as the
hydrazide couplingmethod they used. It seems less likely that
animal differences (Sprague–Dawley rats versus Wag/Rij
rats in our study) caused the difference with our observations.
In any case, the differences between the results in these two
studies underscore the influence of liposomal characteristics
and antibody conjugation techniques on the pharmacoki-
netics of follow-up doses of plain as well as IL.
It is well recognized that liposomal size has strong impli-
cations on the pharmacokinetics. The liposomes used in the
Fig. 3. Comparison of the pharmacokinetic profiles of plain liposomes containing either PEG-PE 2000 or PEG-PE 3000. Data are means of three
experimentsF S.D.
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present study were around 135 nm in diameter and thus
slightly larger than those in other pharmacokinetic studies on
IL [18,31]. Therefore, we also performed experiments on the
effect of repeated injection using liposomes of the same
composition but with a size of around 90 nm. The antibody
density on the smaller liposomes of about 18 IgG per
liposome is identical to that on the liposomes described by
Harding et al. [22]. The pharmacokinetic data in Table 4
demonstrate that a decrease in particle size leads to an
increase in circulation time of the Cyanur IL. Furthermore,
these data confirm and emphasize the differences between
terminal-coupled and conventional IL, which are even more
conspicuous for the 90-nm liposomes than for the larger
liposomes in Table 3. Cyanur 3 and 5 display a very long
circulation time, whereas N-Glut IL and control liposomes
behave similar to the larger liposomes with relatively short
half-lifes. Concomitantly, the liver uptake of the latter two
preparations was higher than that of the Cyanur preparations.
4. Conclusions
We investigated the influence of repeated injections of
liposomes on liposome pharmacokinetics, an aspect of the
therapeutic use of (immuno)liposomes that has attracted little
attention up to now.
Two types of IL were prepared which were identical with
respect to antibody density and orientation; one in which the
antibody was coupled directly to the bilayer lipids and
another in which it was coupled to the terminal end of a bi-
layer-anchored PEG chain. This allowed us to correlate dif-
ferences in pharmacokinetics with structural liposome para-
meters such as antibody accessibility or steric stabilization.
The elimination kinetics in naive rats demonstrates that
coupled antibodies strongly increase the elimination rate,
and because the Cyanur-PEG-PE IL display the shortest half-
life, elimination may directly be correlated with better anti-
body exposure at the liposomal surface.
However, after a second injection, elimination kinetics no
longer obeys this simple rule. A second dose of plain pegy-
lated liposomes was rapidly eliminated. Obviously, the steric
barrier of the liposomes by PEG-PE seems to be less efficient
in reducing opsonization and immune reactions. However, an
active role of PEG-PE in eliciting specific antibodies could
not be established. These data could have implications for the
therapeutic application of pegylated liposomes as drug deli-
very systems.
The coupled antibodies seem to play a less important role
in increasing the elimination than is often assumed, because
IL were eliminated not faster than control liposomes. This
study for the first time directly compares the behavior of
different types of IL upon repeated injections and demon-
strates a relatively low immunogenicity of our Cyanur-PEG-
PE IL. Although we do not fully understand this phenom-
enon at this point, it is obvious that the applied antibody
coupling method is an important parameter in the repeated-
injection pharmacokinetics. These experiments confirm the
biocompatibility of the Cyanur-PEG-PE IL, whereas their
relatively long circulation time upon repeated injections
demonstrates their potential as therapeutic drug delivery
vehicles.
Further experiments, which should consider changes in
the application intervals, modifications in the coupled anti-
bodies or the use of Fab fragments could shed more light on
this behavior.
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